Hisazumi H, Nakajima K
Dept. of Urology, School of Medicine, Kanazawa University.
Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-2):1382-6.
Eight-MHz radiofrequency hyperthermia (H) using Thermotron-RF8, and its combination with irradiation (RH), anticancer drugs (CH) or anticancer drugs plus irradiation (CRH), were carried out for a total of 93 urological malignancies: 19 cases of renal cancer, 3 of renal pelvic cancer, 4 of ureteral cancer 39 of bladder cancer, 8 of prostatic cancer, 14 of metastatic lesion of urological cancers and 6 of other urological cancers. All had failed in previous treatments, or had not undergone surgery because of their poor general condition. Nine cases, including 1 of renal cancer, 1 of ureteral cancer, 4 of bladder cancer, 2 of prostatic cancer and 1 of metastatic lesion of bladder cancer, were treated with (H). Fifty cases, including 4 renal cancer cases, 20 bladder cancer cases and 6 prostatic cancer cases, were treated with (RH). Eight of the 19 cases of renal cancer were treated with mitomycin C-microcapsule (MMC-mc) embolization prior to radiohyperthermia (CRH). The remaining 6 cases of renal cancer received embolization with MMC-mc followed by RE-heating (CH). Eighteen of the 48 cases of urothelial cancer or its metastasis, including 1 of renal pelvic cancer, 15 of bladder a cancer and 2 of metastatic lesion of bladder, received a combined treatment of intravenous THP-adriamycin, one of the derivatives of adriamycin and RE-heating (CH). In the remaining 2 cases, one received (CH), and the other received (CRH). Hyperthermia was given twice a week for a total of 10 sessions in 5 weeks. Intratumoral temperature was kept above 42.5 degrees C for 30 to 40 minutes during a one-hour heating. Complete tumor regression was obtained in 9 bladder cancer cases. Partial tumor regression, defined as a regression of 50% or more, was obtained in 17 cases. A pain relief was attained in 18 of 23 patients with intractable pain due to local tumor infiltration. As side effects, mild skin burns were observed in 21 cases. Ten obese cases, having subcutaneous tissue 15mm thick or more, developed fat tissue induration after treatment.
使用Thermotron-RF8进行8兆赫射频热疗(H),并将其与放疗(RH)、抗癌药物(CH)或抗癌药物加放疗(CRH)联合应用于总共93例泌尿生殖系统恶性肿瘤患者:19例肾癌、3例肾盂癌、4例输尿管癌、39例膀胱癌、8例前列腺癌、14例泌尿生殖系统癌症转移灶及6例其他泌尿生殖系统癌症。所有患者既往治疗均失败,或因全身状况差未接受手术治疗。9例患者,包括1例肾癌、1例输尿管癌、4例膀胱癌、2例前列腺癌和1例膀胱癌转移灶,接受了(H)治疗。50例患者,包括4例肾癌、20例膀胱癌和6例前列腺癌,接受了(RH)治疗。19例肾癌中的8例在射频热疗(CRH)前接受了丝裂霉素C微胶囊(MMC-mc)栓塞治疗。其余6例肾癌患者接受MMC-mc栓塞后再加热(CH)治疗。48例尿路上皮癌或其转移灶患者中的18例,包括1例肾盂癌、15例膀胱癌和2例膀胱癌转移灶,接受了静脉注射阿霉素衍生物之一的THP-阿霉素和再加热的联合治疗(CH)。其余2例患者,1例接受了(CH)治疗,另1例接受了(CRH)治疗。热疗每周进行2次,共5周,每次10个疗程。在1小时加热过程中,瘤内温度保持在42.5℃以上30至40分钟。9例膀胱癌患者肿瘤完全消退。17例患者肿瘤部分消退,定义为消退50%或更多。23例因局部肿瘤浸润导致顽固性疼痛的患者中有18例疼痛缓解。作为副作用,21例患者出现轻度皮肤烧伤。10例肥胖患者,皮下组织厚度达15毫米或更厚,治疗后出现脂肪组织硬结。